First Tracks Biotherapeutics, Inc. Form 4 Filings

First Tracks Biotherapeutics, Inc. (symbol: TRAX) is the issuer of record for a Form 4 filing submitted to the SEC.

First Tracks Biotherapeutics, Inc. (symbol: TRAX) is the issuer of record for a Form 4 filing submitted to the SEC.

First Tracks Biotherapeutics, Inc. (symbol: TRAX) is the issuer of record for a Form 4 filing submitted to the SEC.

STONE BENJAMIN reported acquisition or exercise transactions in this Form 4 filing.

First Tracks Biotherapeutics, Inc. granted Chief Business Officer Benjamin Stone 60,492 performance-based restricted stock units (PSUs) on August 2, 2026, each representing one share of common stock. The PSUs were earned upon certified achievement of performance criteria and vest over two years: 50% on August 2, 2027 and 50% on July 1, 2028, subject to his continued service on each vesting date. Following this award, Stone directly holds 77,159 PSUs.

Lizzul Paul F. reported acquisition or exercise transactions in this Form 4 filing.

First Tracks Biotherapeutics, Inc. granted its Chief Medical Officer, Paul F. Lizzul, 60,492 performance stock units (PSUs) on August 2, 2026, after achievement of performance criteria certified by the Compensation Committee. Each PSU represents a conditional right to one share of common stock. The PSUs vest and settle over two years, with 50% vesting on August 2, 2027 and 50% on July 1, 2028, subject to his continued service, bringing his total PSUs to 77,159.

First Tracks Biotherapeutics, Inc. President and CEO Daniel Faga reported an acquisition of 193,576 performance stock units (PSUs), each representing a conditional right to receive one share of common stock. These PSUs were earned upon achievement of performance criteria certified on August 2, 2026, and vest 50% on August 2, 2027 and 50% on July 1, 2028, subject to his continued service. Following this award, Faga holds 387,156 PSUs in total.

First Tracks Biotherapeutics director Rita Jain exercised equity awards to acquire additional common shares. On June 15, 2026, she acquired 7,330 shares of common stock through the exercise or conversion of restricted stock units at no cash exercise price, increasing her direct holdings to 19,194 shares.

The filing shows two RSU tranches of 1,300 and 6,030 units converting into common stock. Footnotes explain that each RSU represents a contingent right to receive one share upon settlement for no consideration, with vesting tied to continued service through June 15, 2026.

First Tracks Biotherapeutics director John P. Schmid exercised restricted stock units into common shares. On June 15, 2026, he acquired 6,030 shares of Common Stock at a reported price of $0.00 per share through an RSU conversion. Following this transaction, he directly holds 37,652 shares of Common Stock. The RSU award represented a contingent right to receive one share of Common Stock per unit upon settlement for no consideration.

First Tracks Biotherapeutics director John A. Orwin exercised restricted stock units to acquire 6,030 shares of Common Stock. The derivative exercise occurred on June 15, 2026 at an exercise price of $0.00 per share, increasing his direct holdings to 16,695 Common Stock shares.

The transaction reflects settlement of an RSU award, where each RSU represented a contingent right to receive one share of Common Stock for no consideration. The RSUs vested 100% on June 15, 2026, subject to his continued service to the company on that vesting date.

First Tracks Biotherapeutics director Ware J. Anthony exercised restricted stock units into common shares. On June 15, 2026, 6,030 Restricted Stock Units converted into 6,030 shares of Common Stock at no cost upon vesting. Following this settlement, he directly holds 15,660 common shares. No shares were sold in this filing.

First Tracks Biotherapeutics director Magda Marquet exercised restricted stock units into common shares. On June 15, 2026, she converted 6,030 restricted stock units into 6,030 shares of common stock for no cash consideration, reflecting compensation rather than a market purchase or sale.

Following the transaction, she directly owns 15,960 shares of common stock. The RSU award vested 100% on June 15, 2026, contingent on her continued service to the company through that date.

First Tracks Biotherapeutics director Dennis M. Fenton exercised restricted stock units into common shares as part of his equity compensation. On June 15, 2026, 6,030 RSUs converted into 6,030 shares of common stock at no cash cost, bringing his direct holdings to 10,995 shares. The RSUs vested in full on that date, with no remaining RSU balance reported.

First Tracks Biotherapeutics director Dennis M. Fenton received new equity awards. On May 12, 2026, he was granted stock options for 7,000 shares of common stock at an exercise price of $17.81 per share, vesting monthly over one year starting June 12, 2026.

He was also granted 2,500 restricted stock units, each representing one share of common stock for no cash payment. These RSUs vest in full at the company’s 2027 annual meeting of shareholders, if he continues providing service through that date.

First Tracks Biotherapeutics director Rita Jain received new equity awards. On May 12, 2026, she was granted options for 7,000 shares of common stock at an exercise price of $17.81 per share, vesting monthly over one year starting June 12, 2026. She also received 2,500 restricted stock units, each convertible into one share of common stock, which vest in full on the date of the company’s 2027 annual meeting of shareholders, in both cases contingent on continued service.

First Tracks Biotherapeutics, Inc. director Magda Marquet received equity-based compensation awards. She was granted stock options for 7,000 shares of common stock at an exercise price of 17.81 per share, expiring on May 11, 2036, and 2,500 restricted stock units. The options vest in 12 equal monthly installments starting June 12, 2026, while all RSUs vest on the date of the company’s 2027 annual shareholders meeting, in each case subject to continued service.

First Tracks Biotherapeutics director equity grants: Director John A. Orwin received stock options for 7,000 shares of Common Stock at an exercise price of $17.81 per share and 2,500 Restricted Stock Units on May 12, 2026, as compensation awards, not open‑market trades.

The 2,500 RSUs each represent one share of Common Stock for no cash cost and vest 100% on the date of the company’s 2027 annual shareholder meeting, if he continues serving the company. The 7,000 stock options vest in 12 equal monthly installments starting June 12, 2026, through full vesting, also conditioned on continued service.

First Tracks Biotherapeutics director John P. Schmid received new equity awards as part of his compensation. On May 12, 2026, he was granted stock options for 7,000 shares of common stock at an exercise price of $17.81 per share, vesting in equal monthly installments over 12 months starting June 12, 2026. He was also granted 2,500 restricted stock units, each representing one share of common stock for no cash payment, which vest in full on the date of the company’s 2027 annual meeting of shareholders, as long as he continues to provide service to the company.

First Tracks Biotherapeutics director Ware J. Anthony reported new equity compensation awards. On May 12, 2026, he received stock options covering 7,000 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036. These options vest in equal monthly installments, with 1/12 of the total vesting each month starting June 12, 2026, as long as he continues serving the company.

He was also granted 2,500 restricted stock units, each representing one share of common stock for no cash payment. These RSUs vest 100% on the date of First Tracks’ 2027 annual meeting of shareholders, subject to his continued service.

First Tracks Biotherapeutics director Ware J. Anthony received new equity awards. He was granted stock options for 42,000 shares of common stock at an exercise price of $17.81 per share and 15,000 restricted stock units, both as compensation awards rather than open‑market purchases.

The 42,000 stock options vest in equal monthly installments over 12 months starting on June 12, 2026, and expire on May 11, 2036, if not exercised. The 15,000 RSUs vest 100% on the date of the company’s 2027 annual meeting of shareholders, subject to continued service, and each RSU will settle into one share for no cash consideration.

In addition to these grants, he also holds options to purchase up to 131,585 additional shares of common stock under prior awards, which continue to vest according to their own terms.

First Tracks Biotherapeutics director John P. Schmid received new equity awards as part of his compensation. He was granted stock options covering 42,000 shares of common stock at an exercise price of $17.81 per share, expiring on 2036-05-11.

The option vests in equal monthly installments, with 1/12 of the shares vesting each month starting on 2026-06-12, as long as he continues serving the company. Schmid also received 15,000 restricted stock units, each representing a right to one share of common stock at no cost upon settlement.

These RSUs vest 100% on the date of First Tracks Biotherapeutics’ 2027 annual shareholder meeting, subject to continued service. In addition to the newly granted 42,000 options, he already holds options to purchase up to an aggregate of 107,320 shares of common stock that vest according to their existing terms.

First Tracks Biotherapeutics director Magda Marquet received new equity awards as part of her compensation. She was granted options to buy 42,000 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036. These options vest monthly, with 1/12 of the total vesting each month starting on June 12, 2026, as long as she continues serving the company.

She also received 15,000 restricted stock units, each representing the right to receive one share of common stock for no cash payment. All of these RSUs vest on the date of First Tracks’ 2027 annual meeting of shareholders, subject to her continued service. In addition to this new option grant, she already holds options to purchase up to 70,104 shares of common stock that vest according to their existing terms.

First Tracks Biotherapeutics director Rita Jain received new equity awards in the form of options and restricted stock units. She was granted options to buy 42,000 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036.

She also received 15,000 restricted stock units, each representing one share of common stock upon settlement for no cash consideration. The RSUs vest 100% on the date of the company’s 2027 annual shareholder meeting, while the options vest in 12 equal monthly installments starting June 12, 2026 as long as she continues serving the company.

First Tracks Biotherapeutics director John A. Orwin received new equity awards. He was granted options to buy 42,000 shares of common stock at an exercise price of $17.81 per share, vesting in 12 equal monthly installments starting on June 12, 2026, as long as he continues serving the company.

Orwin also received 15,000 restricted stock units, each representing one share of common stock for no cash cost upon settlement. These RSUs vest 100% on the date of the company’s 2027 annual shareholder meeting, subject to continued service. A footnote notes he also holds other options covering up to 55,181 shares that vest under their existing terms.

First Tracks Biotherapeutics director Dennis M. Fenton received new equity awards as part of his compensation. He was granted options to buy 42,000 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036. These options vest in equal monthly installments over 12 months beginning June 12, 2026, so he earns them gradually by continuing to serve the company.

He was also granted 15,000 restricted stock units, each representing one share of common stock for no cash payment. These RSUs vest in full on the date of the company’s 2027 annual shareholder meeting, if he is still providing service. In addition to the 42,000 new options, he holds other options to purchase up to 97,827 shares that vest under their existing terms.

First Tracks Biotherapeutics granted Chief Business Officer Benjamin Stone new equity awards tied to the company’s common stock. He received an option to buy 72,300 shares at an exercise price of $17.81 per share, expiring on May 11, 2036. The option vests 25% on May 12, 2027, then in equal monthly installments over four years, conditioned on continued service.

Stone was also awarded 26,700 restricted stock units, each representing one share of common stock upon settlement for no consideration. These RSUs vest 25% annually starting on May 12, 2027, also subject to ongoing service. In addition to the new grant, he already holds options to purchase up to 337,140 shares of common stock under existing award terms.

First Tracks Biotherapeutics, Inc. reported that President and CEO Daniel Faga received new equity awards as part of his compensation. He was granted options to purchase 271,100 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036.

These stock options vest 25% on May 12, 2027, then in equal monthly installments over 48 months, contingent on continued service. Faga also received 100,200 restricted stock units, each representing one share of common stock for no cash consideration, vesting 25% annually from May 12, 2027 until fully vested, also subject to continued service. A footnote states he holds additional options to purchase up to 1,035,941 shares that vest under their own terms.

First Tracks Biotherapeutics Chief Financial Officer Ajim Tamboli received new equity awards as part of compensation. On May 12, 2026, he was granted options to purchase 13,600 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036.

The option vests 25% on May 12, 2027 and then in equal monthly installments over the following three years, contingent on continued service. He also received 5,000 restricted stock units, with 25% of the RSUs vesting annually starting on May 12, 2027, also subject to continued service.

In addition to this new grant of 13,600 options, he holds other options covering up to 123,700 shares of common stock that vest according to their existing terms. These awards are non-cash grants and do not represent open-market share purchases or sales.

First Tracks Biotherapeutics Chief Medical Officer Paul F. Lizzul received new equity awards. He was granted employee stock options for 72,300 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036. These options vest 25% on May 12, 2027, then 1/48 of the total shares monthly until fully vested, contingent on continued service.

He also received 26,700 restricted stock units, each representing a right to receive one share of common stock for no cash payment. The RSUs vest 25% annually starting on May 12, 2027, subject to ongoing service. There were no open-market purchases or sales reported. A footnote states he also holds separate options to purchase up to 507,310 shares of common stock that vest under their own terms.